A recent study suggests that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional lifestyle plans.
Research printed in a prominent health publication points out that while obese individuals can lose substantial amounts of their total mass while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"People using these treatments need to be informed of the potential of rapid rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
Such speed of recovery implies a return to starting weight within about 18 months.
Weighing Approaches
The analysis, which examined dozens of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team note that people who shed pounds through dieting generally see a slower weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Quick Rebound
Nutrition scientists propose the way of the drugs accounts for the heightened regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication leads to appetite is no longer kept in check, making binge eating a significant risk."
A Chronic Disease?
The NHS recommend the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians contend that, considering the likelihood of relapse, the therapy should be considered ongoing.
This perspective is reinforced by pharmaceutical companies, who note that the results "emphasize the chronic nature of excess weight," comparing it to managing conditions like hypertension.
Patient Experiences
Individuals who have stopped the medication explain a powerful resurgence of hunger.
"It felt as if a trigger activating and you're instantly starving," described a patient.
The struggle is exacerbated if individuals have not developed sustainable dietary or behavioural modifications during therapy.
Significant Use
Recent estimates show that a significant number of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is more common among women than men.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, experts stress that while GLP-1 drugs are powerful tools for weight loss, they are not a magic solution and long-term success hinges on integrated behavioural management.
